mavrilimumab
Kiniksa
['ease,(-please),(-disease),(-incrrease),(-decrease)', 'axspa']
papagoras et al. serum gm-csf increased in axspa and persists despite tnfi. are we going to have a trial of mavrilimumab in axspa then? #acr22 abstr#1156 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC